Viatris Agrees to Settle EpiPen Antitrust Litigation for $264 Million
“Viatris, the drugmaker previously known as Mylan, announced on Monday that it had agreed to pay $264 million to settle a class-action lawsuit that alleged the company was involved in an illegal scheme to monopolize the market for epinephrine auto-injector devices known as EpiPens, which are,” reports Jesus Jimenez in The New York Times.
“The proposed settlement, which needs to be approved by a judge, would resolve a legal battle that began after Mylan, in 2016, raised the price for a pack of two EpiPens to $608 from $100, the price since 2007, according to court documents. In the lawsuit, a group of plaintiffs made up of consumers, health insurance companies and other.”
